Original Articles
Evaluation of SpyGlass DS for longitudinal extensions of bile duct cancer
2020 Volume 34 Issue 1 Pages 60-67
Details
2020 Volume 34 Issue 1 Pages 60-67
We evaluated SpyGlass DS for longitudinal extensions of bile duct cancer. The present study included 17 patients underwent a surgical line of resection (15 resections, 2 unresections). We compared the accuracy of diagnosing longitudinal extensions using computed tomography (CT), intraductal ultrasonography (IDUS), cholangiography, and SpyGlass DS.
In resected cases, the false-positive rate was 6.7% for CT, 25.0% for IDUS, and 20.0% for cholangiography. The findings of Cholangioscopy-guided biopsies revealed normal mucosa in 86.7% of cases, irregular mucosa in 13.3%, and not carcinoma. R0 resection was achieved in all cases, with SpyGlass DS showing a diagnostic accuracy of 100%. For unresected cases, positive rates were 50.0% for CT, 50.0% for IDUS, and 100% for cholangiography. The findings of cholangioscopy-guided biopsies showed carcinomas, diagnosed as unresectable.
The findings of SpyGlass DS cholangioscopy-guided biopsies are useful for evaluating longitudinal extensions of bile duct cancer.
